Prescribing overview
Reverses dexmedetomidine- or medetomidine-associated sedation and analgesia in dogs.
Reversal also removes alpha-2-associated pain relief. A separate analgesic plan may be necessary before recovery.
Key prescribing checks
- Read the product-specific safety section and monitoring plan before selecting a treatment.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary labelReversal of dexmedetomidine or medetomidine sedation and analgesia
Intramuscular administration; the original sedative and its route determine label-table selection.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Competitively blocks alpha-2 receptors; it does not reverse other anesthetic or analgesic classes.
Absorption, distribution, metabolism and elimination
Absorbed rapidly after intramuscular injection, with hepatic metabolism and mainly urinary metabolite excretion.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Antisedan
US veterinary label; Intramuscular injectable solution.
Contraindications · when not to use
- Hypersensitivity; the label also excludes dogs with cardiac, respiratory, hepatic or renal disease, shock, severe debilitation, or extreme heat/cold/fatigue stress.
Precautions & monitoring
- Abrupt arousal and sedation relapse require protected recovery. Reproductive use is not recommended; young or very small dogs were not evaluated.
Selected product scope; does not establish suitability for other species, routes or formulations.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vomiting, salivation, diarrhea, tremors, excitement or apprehension can occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this reference. The veterinarian must select the exact product-label protocol for the patient, indication and route; this entry does not enable an automatic dose.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Antisedan
US veterinary label; Intramuscular injectable solution.
- Reverses the alpha-2 component only; residual effects of other anesthetics still require monitoring.
Monitoring
Observe respiration, heart rate, temperature, recurrent sedation and pain until recovery remains stable.
Client counseling
Arousal is not proof that all anesthetics have worn off. Handle recovering dogs carefully.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Follow current vial storage labeling and avoid accidental human exposure.
Brands, formulations & ingredient identity
Active ingredients
Atipamezole hydrochloride
This US Antisedan scope does not establish labeled feline or equine use.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Antisedan
- Formulation
- Intramuscular injectable solution
- Label / product scope
- Dogs
Intramuscular administration; the original sedative and its route determine label-table selection.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →